Aret Kahyaoglu, MD
Pediatrics · Hackensack, NJNPI 1811023682
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.6% of the total across 385 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $1,181 and has fallen 64.3% since, to $421 in 2025. Among pediatrics clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 385 payments — averaging $13.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$758
- Boehringer Ingelheim$602
- Novo Nordisk$415
- Pfizer$394
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$391
- Amarin Pharma, Inc.$311
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,88097%
- Education$1693%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 88 | $758 |
| Boehringer Ingelheim | 43 | $602 |
| Novo Nordisk | 26 | $415 |
| Pfizer | 29 | $394 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 33 | $391 |
| Amarin Pharma, Inc. | 24 | $311 |
| AstraZeneca(2 entities) | 15 | $218 |
| Amgen | 15 | $213 |
| GSK | 13 | $190 |
| Johnson & Johnson | 9 | $188 |
| Astellas Pharma US Inc | 6 | $186 |
| Arbor Pharmaceuticals, Inc. | 16 | $147 |
| Esperion Therapeutics, Inc. | 11 | $138 |
| Azurity Pharmaceuticals, Inc. | 8 | $121 |
| Exact Sciences | 5 | $110 |
| Lilly USA, LLC | 7 | $98 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $88 |
| Merck | 6 | $83 |
| Almatica Pharma LLC | 5 | $69 |
| Kowa Pharmaceuticals America, Inc. | 3 | $51 |
| Althera Pharmaceuticals LLC | 3 | $49 |
| E.r. Squibb & Sons, L.L.C. | 3 | $43 |
| Xeris Pharmaceuticals, Inc. | 2 | $32 |
| Jazz Pharmaceuticals Inc. | 2 | $29 |
| Novartis | 1 | $26 |
| Renalytix AI, Inc. | 1 | $20 |
| Seqirus USA Inc | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
How this compares
$5,049 in reported general payments places this provider in the 95th percentile of 1,890 pediatrics providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 151 | $173,496 |
| OzempicSemaglutide | 85 | $107,206 |
| JanuviaSitagliptin Phosphate | 44 | $65,558 |
| ProliaDenosumab | 31 | $50,799 |
| JardianceEmpagliflozin | 46 | $50,355 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $40,003 |
| XareltoRivaroxaban | 28 | $37,016 |
| RybelsusSemaglutide | 25 | $34,229 |
| FarxigaDapagliflozin Propanediol | 25 | $27,490 |
| TradjentaLinagliptin | 13 | $18,556 |
| Dexlansoprazole DrDexlansoprazole | 52 | $12,148 |
| MounjaroTirzepatide | 11 | $11,887 |
| MyrbetriqMirabegron | 15 | $10,338 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $9,679 |
| LinzessLinaclotide | 17 | $8,490 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $394 | $173,496151 claims |
| Novo NordiskOzempic, Rybelsus | $415 | $141,435110 claims |
| MerckJanuvia, Janumet | $83 | $75,23757 claims |
| Boehringer IngelheimJardiance, Tradjenta | $602 | $68,91159 claims |
| AmgenProlia | $213 | $50,79931 claims |
| GSKTrelegy Ellipta | $190 | $40,00348 claims |
| AstraZenecaFarxiga, Nexium, Bevespi Aerosphere | $218 | $38,86453 claims |
| Johnson & JohnsonXarelto | $188 | $37,01628 claims |
| Lilly USA, LLCMounjaro | $98 | $11,88711 claims |
| Astellas Pharma US IncMyrbetriq | $186 | $10,33815 claims |
| AbbVieLinzess | $758 | $8,49017 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $147 | $7,64811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,890 pediatrics providers in New Jersey.
Other pediatrics in Hackensack
- Steven MateretskyHackensack$290K
- Melanie DegliuominiHackensack$17K
- Fred HirschenfangHackensack$3K
- Gomathi AdhiyamanHackensack$3K
- Joseph FruchterHackensack$3K
- Amy ChartoffHackensack$3K
- Sara RaymondMorristown$288K
- Andrew MulbergCamden$264K
- Bram GreenbergLakewood$200K
- David ApelianBoonton$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.